# Chemours Co: financial statements, quarterly

CC · NYSE · CIK 1627223 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cc.md) · [Financials](/companies/cc/financials.md) · [Filings](/companies/cc/filings.md) · [Insiders](/companies/cc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,501](/filings/0000950170-25-021787.md) | [1,368](/filings/0000950170-25-021787.md) | [1,362](/filings/0001193125-26-065201.md) | [1,554](/filings/0001193125-26-065201.md) | [1,508](/filings/0001193125-26-065201.md) | [1,359](/filings/0001193125-26-065201.md) | [1,368](/filings/0001627223-26-000011.md) | [1,615](/filings/0001627223-26-000024.md) | [1,495](/filings/0001193125-26-065201.md) | [1,329](/filings/0001193125-26-065201.md) | [1,381](/filings/0001627223-26-000011.md) | [1,591](/filings/0001627223-26-000024.md) |
| Cost of revenue | $m | [1,228](/filings/0000950170-25-021787.md) | [1,113](/filings/0000950170-25-021787.md) | [1,078](/filings/0001193125-26-065201.md) | [1,246](/filings/0001193125-26-065201.md) | [1,222](/filings/0001193125-26-065201.md) | [1,094](/filings/0001193125-26-065201.md) | [1,132](/filings/0001627223-26-000011.md) | [1,337](/filings/0001627223-26-000024.md) | [1,262](/filings/0001193125-26-065201.md) | [1,174](/filings/0001193125-26-065201.md) | [1,169](/filings/0001627223-26-000011.md) | [1,305](/filings/0001627223-26-000024.md) |
| Gross profit | $m | [273](/filings/0000950170-25-021787.md) | [251 d](/filings/0001193125-26-065201.md) | [284](/filings/0000950170-25-064546.md) | [308](/filings/0000950170-25-103212.md) | [286](/filings/0001193125-25-269765.md) | [265](/filings/0001193125-26-065201.md) | [236](/filings/0001627223-26-000011.md) | [278](/filings/0001627223-26-000024.md) | [233](/filings/0001193125-25-269765.md) | [156 d](/filings/0001193125-26-065201.md) | [212](/filings/0001627223-26-000011.md) | [286](/filings/0001627223-26-000024.md) |
| Research and development | $m | [28.0](/filings/0000950170-24-120270.md) | [26.0 d](/filings/0001193125-26-065201.md) | [28.0](/filings/0000950170-25-064546.md) | [26.0](/filings/0000950170-25-103212.md) | [29.0](/filings/0001193125-25-269765.md) | [26.0 d](/filings/0001193125-26-065201.md) | [27.0](/filings/0001627223-26-000011.md) | [28.0](/filings/0001627223-26-000024.md) | [26.0](/filings/0001193125-25-269765.md) | [27.0 d](/filings/0001193125-26-065201.md) | [26.0](/filings/0001627223-26-000011.md) | [27.0](/filings/0001627223-26-000024.md) |
| Selling, general and administrative | $m | [165](/filings/0000950170-24-120270.md) | [219 d](/filings/0001193125-26-065201.md) | [137](/filings/0000950170-25-064546.md) | [154](/filings/0000950170-25-103212.md) | [137](/filings/0001193125-25-269765.md) | [170 d](/filings/0001193125-26-065201.md) | [123](/filings/0001627223-26-000011.md) | [424](/filings/0001627223-26-000024.md) | [122](/filings/0001193125-26-065201.md) | [130 d](/filings/0001193125-26-065201.md) | [147](/filings/0001627223-26-000011.md) | [469](/filings/0001627223-26-000024.md) |
| Interest expense | $m | [55.0](/filings/0000950170-24-120270.md) | [63.0 d](/filings/0001193125-26-065201.md) | [63.0](/filings/0000950170-25-064546.md) | [66.0](/filings/0000950170-25-103212.md) | [68.0](/filings/0001193125-25-269765.md) | [67.0 d](/filings/0001193125-26-065201.md) | [66.0](/filings/0001627223-26-000011.md) | [67.0](/filings/0001627223-26-000024.md) | [68.0](/filings/0001193125-25-269765.md) | [68.0 d](/filings/0001193125-26-065201.md) | [69.0](/filings/0001627223-26-000011.md) | [68.0](/filings/0001627223-26-000024.md) |
| Income tax | $m | [1.0](/filings/0000950170-24-120270.md) | [(38.0) d](/filings/0001193125-26-065201.md) | [16.0](/filings/0000950170-25-064546.md) | [9.0](/filings/0000950170-25-103212.md) | [0.0](/filings/0001193125-25-269765.md) | [12.0](/filings/0001193125-26-065201.md) | [5.0](/filings/0001627223-26-000011.md) | [131](/filings/0001627223-26-000024.md) | [(8.0)](/filings/0001193125-26-065201.md) | [(19.0) d](/filings/0001193125-26-065201.md) | [7.0](/filings/0001627223-26-000011.md) | [273](/filings/0001627223-26-000024.md) |
| Net income | $m | [12.0](/filings/0000950170-25-021787.md) | [(18.0)](/filings/0000950170-25-021787.md) | [54.0](/filings/0001193125-26-065201.md) | [60.0](/filings/0001193125-26-065201.md) | [(32.0)](/filings/0001193125-26-065201.md) | [(11.0)](/filings/0001193125-26-065201.md) | [(5.0)](/filings/0001627223-26-000011.md) | [(380)](/filings/0001627223-26-000024.md) | [46.0](/filings/0001193125-26-065201.md) | [(47.0)](/filings/0001193125-26-065201.md) | [(29.0)](/filings/0001627223-26-000011.md) | [(274)](/filings/0001627223-26-000024.md) |
| Diluted EPS | $ per share | [0.08](/filings/0000950170-25-021787.md) | [(0.12)](/filings/0000950170-25-021787.md) | [0.36](/filings/0001193125-26-065201.md) | [0.39](/filings/0001193125-26-065201.md) | [(0.22)](/filings/0001193125-26-065201.md) | [(0.08)](/filings/0001193125-26-065201.md) | [(0.03)](/filings/0001627223-26-000011.md) | [(2.53)](/filings/0001627223-26-000024.md) | [0.31](/filings/0001193125-26-065201.md) | [(0.31)](/filings/0001193125-26-065201.md) | [(0.19)](/filings/0001627223-26-000011.md) | [(1.81)](/filings/0001627223-26-000024.md) |
| Basic EPS | $ per share | [0.08](/filings/0000950170-25-021787.md) | [(0.12)](/filings/0000950170-25-021787.md) | [0.36](/filings/0001193125-26-065201.md) | [0.40](/filings/0001193125-26-065201.md) | [(0.22)](/filings/0001193125-26-065201.md) | [(0.08)](/filings/0001193125-26-065201.md) | [(0.03)](/filings/0001627223-26-000011.md) | [(2.53)](/filings/0001627223-26-000024.md) | [0.31](/filings/0001193125-26-065201.md) | [(0.31)](/filings/0001193125-26-065201.md) | [(0.19)](/filings/0001627223-26-000011.md) | [(1.81)](/filings/0001627223-26-000024.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [852](/filings/0000950170-23-056036.md) | [1,203](/filings/0001193125-26-065201.md) | [746](/filings/0000950170-24-050551.md) | [604](/filings/0000950170-24-089414.md) | [596](/filings/0000950170-24-120270.md) | [713](/filings/0001193125-26-065201.md) | [464](/filings/0000950170-25-064546.md) | [502](/filings/0000950170-25-103212.md) | [613](/filings/0001193125-25-269765.md) | [670](/filings/0001627223-26-000024.md) | [563](/filings/0001627223-26-000011.md) | [671](/filings/0001627223-26-000024.md) |
| Current assets | $m | [3,683](/filings/0000950170-23-056036.md) | [3,844](/filings/0001193125-26-065201.md) | [3,610](/filings/0000950170-25-064546.md) | [2,938](/filings/0000950170-25-064546.md) | [3,076](/filings/0000950170-25-064546.md) | [3,017](/filings/0001193125-26-065201.md) | [2,933](/filings/0000950170-25-064546.md) | [3,100](/filings/0000950170-25-103212.md) | [3,207](/filings/0001193125-25-269765.md) | [3,001](/filings/0001627223-26-000024.md) | [2,928](/filings/0001627223-26-000011.md) | [3,094](/filings/0001627223-26-000024.md) |
| Total assets | $m | [7,948](/filings/0000950170-23-056036.md) | [8,241](/filings/0001193125-26-065201.md) | [7,983](/filings/0000950170-25-064546.md) | [7,246](/filings/0000950170-25-064546.md) | [7,457](/filings/0000950170-25-064546.md) | [7,509](/filings/0001193125-26-065201.md) | [7,376](/filings/0001193125-26-065201.md) | [7,462](/filings/0001193125-26-065201.md) | [7,546](/filings/0001193125-26-065201.md) | [7,382](/filings/0001627223-26-000024.md) | [7,267](/filings/0001627223-26-000011.md) | [7,150](/filings/0001627223-26-000024.md) |
| Current liabilities | $m | [2,925](/filings/0000950170-24-037171.md) | [2,487](/filings/0001193125-26-065201.md) | [2,232](/filings/0000950170-25-064546.md) | [1,560](/filings/0000950170-25-064546.md) | [1,786](/filings/0000950170-25-064546.md) | [1,820](/filings/0001193125-26-065201.md) | [1,668](/filings/0001193125-26-065201.md) | [1,827](/filings/0001193125-26-065201.md) | [1,871](/filings/0001193125-26-065201.md) | [1,686](/filings/0001627223-26-000024.md) | [1,609](/filings/0001627223-26-000011.md) | [1,861](/filings/0001627223-26-000024.md) |
| Total liabilities | $m | [7,199](/filings/0000950170-24-037171.md) | [7,518](/filings/0001193125-26-065201.md) | [7,228](/filings/0000950170-25-064546.md) | [6,530](/filings/0000950170-25-064546.md) | [6,812](/filings/0000950170-25-064546.md) | [6,937](/filings/0001193125-26-065201.md) | [6,809](/filings/0001193125-26-065201.md) | [7,232](/filings/0001193125-26-065201.md) | [7,270](/filings/0001193125-25-269765.md) | [7,131](/filings/0001627223-26-000024.md) | [7,051](/filings/0001627223-26-000011.md) | [7,198](/filings/0001627223-26-000024.md) |
| Long-term debt | $m | [3,944](/filings/0000950170-23-056036.md) | [3,989](/filings/0001193125-26-065201.md) | [3,970](/filings/0000950170-25-064546.md) | [3,953](/filings/0000950170-25-064546.md) | [3,988](/filings/0000950170-24-120270.md) | [4,059](/filings/0001193125-26-065201.md) | [4,069](/filings/0001193125-26-065201.md) | [4,108](/filings/0001193125-26-065201.md) | [4,104](/filings/0001193125-26-065201.md) | [4,099](/filings/0001627223-26-000024.md) | [4,100](/filings/0001627223-26-000011.md) | [3,838](/filings/0001627223-26-000024.md) |
| Current portion of debt | $m | [39.0](/filings/0000950170-24-037171.md) | [51.0](/filings/0000950170-25-021787.md) | [41.0](/filings/0000950170-24-050551.md) | [37.0](/filings/0000950170-24-089414.md) | [53.0](/filings/0000950170-24-120270.md) | [54.0](/filings/0001193125-26-065201.md) | [43.0](/filings/0000950170-25-064546.md) | [38.0](/filings/0000950170-25-103212.md) | [52.0](/filings/0001193125-25-269765.md) | [42.0](/filings/0001627223-26-000024.md) | [37.0](/filings/0001627223-26-000011.md) | [34.0](/filings/0001627223-26-000024.md) |
| Shareholders' equity | $m | [755](/filings/0000950170-23-056036.md) | [721](/filings/0001193125-26-065201.md) | [753](/filings/0000950170-25-064546.md) | [714](/filings/0000950170-25-064546.md) | [643](/filings/0000950170-25-064546.md) | [571](/filings/0001193125-26-065201.md) | [566](/filings/0001193125-26-065201.md) | [228](/filings/0001193125-26-065201.md) | [274](/filings/0001193125-26-065201.md) | [250](/filings/0001627223-26-000024.md) | [215](/filings/0001627223-26-000011.md) | [(49.0)](/filings/0001627223-26-000024.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [131 d](/filings/0000950170-24-120270.md) | [482 d](/filings/0001193125-26-065201.md) | [(290)](/filings/0000950170-25-064546.md) | [(620) d](/filings/0000950170-25-103212.md) | [139 d](/filings/0001193125-25-269765.md) | [138 d](/filings/0001193125-26-065201.md) | [(112)](/filings/0001627223-26-000011.md) | [93.0 d](/filings/0001627223-26-000024.md) | [146 d](/filings/0001193125-26-065201.md) | [137 d](/filings/0001193125-26-065201.md) | [(44.0)](/filings/0001627223-26-000011.md) | [158 d](/filings/0001627223-26-000024.md) |
| Capital expenditure | $m | [86.0 d](/filings/0000950170-24-120270.md) | [135 d](/filings/0001193125-26-065201.md) | [102](/filings/0000950170-25-064546.md) | [73.0 d](/filings/0000950170-25-103212.md) | [76.0 d](/filings/0001193125-25-269765.md) | [109 d](/filings/0001193125-26-065201.md) | [84.0](/filings/0001627223-26-000011.md) | [43.0 d](/filings/0001627223-26-000024.md) | [41.0 d](/filings/0001193125-25-269765.md) | [45.0 d](/filings/0001193125-26-065201.md) | [49.0](/filings/0001627223-26-000011.md) | [44.0 d](/filings/0001627223-26-000024.md) |
| Dividends paid | $m | [37.0 d](/filings/0000950170-24-120270.md) | [37.0 d](/filings/0001193125-26-065201.md) | [37.0](/filings/0000950170-25-064546.md) | [37.0 d](/filings/0000950170-25-103212.md) | [38.0 d](/filings/0001193125-25-269765.md) | [36.0 d](/filings/0001193125-26-065201.md) | [37.0](/filings/0001627223-26-000011.md) | [13.0 d](/filings/0001627223-26-000024.md) | [13.0 d](/filings/0001193125-25-269765.md) | [15.0 d](/filings/0001193125-26-065201.md) | [13.0](/filings/0001627223-26-000011.md) | [13.0 d](/filings/0001627223-26-000024.md) |
| Share repurchases | $m | [18.0 d](/filings/0000950170-24-120270.md) | [0.0 d](/filings/0001193125-26-065201.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [158](/filings/0000950170-23-056036.md) | [151](/filings/0000950170-24-050551.md) | [149](/filings/0000950170-24-089414.md) | [150](/filings/0000950170-24-120270.md) | [150](/filings/0000950170-25-064546.md) | [150](/filings/0000950170-25-103212.md) | [150](/filings/0001193125-25-269765.md) | [150](/filings/0001627223-26-000011.md) | [150](/filings/0001627223-26-000024.md) | [151](/filings/0001193125-25-269765.md) | [151](/filings/0001627223-26-000011.md) | [151](/filings/0001627223-26-000024.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 150,498,995 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001627223-26-000024.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.